Cargando…

HAE international home therapy consensus document

Hereditary angioedema (C1 inhibitor deficiency, HAE) is associated with intermittent swellings which are disabling and may be fatal. Effective treatments are available and these are most useful when given early in the course of the swelling. The requirement to attend a medical facility for parentera...

Descripción completa

Detalles Bibliográficos
Autores principales:	Longhurst, Hilary J, Farkas, Henriette, Craig, Timothy, Aygören-Pürsün, Emel, Bethune, Claire, Bjorkander, Janne, Bork, Konrad, Bouillet, Laurence, Boysen, Henrik, Bygum, Anette, Caballero, Teresa, Cicardi, Marco, Dempster, John, Gompels, Mark, Gooi, Jimmy, Grigoriadou, Sofia, Huffer, Ursula, Kreuz, Wolfhart, Levi, Marcel M, Long, Janet, Martinez-Saguer, Inmaculada, Raguet, Michel, Reshef, Avner, Bowen, Tom, Zuraw, Bruce
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2010
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2922091/ https://www.ncbi.nlm.nih.gov/pubmed/20667125 http://dx.doi.org/10.1186/1710-1492-6-22

Ejemplares similares

549 Management of Twenty-Five Pediatric Patients with Hereditary Angioedema (Hae) Undergoing Home Treatment—A Clinical Surveillance Program
por: Martinez-Saguer, Inmaculada, et al.
Publicado: (2012)

Risk of angioedema following invasive or surgical procedures in HAE type I and II – the natural history
por: Aygören-Pürsün, E, et al.
Publicado: (2013)

The hereditary angioedema burden of illness study in Europe (HAE-BOIS-Europe): background and methodology
por: Bygum, Anette, et al.
Publicado: (2012)

On demand treatment and home therapy of hereditary angioedema in Germany - the Frankfurt experience
por: Aygören-Pürsün, Emel, et al.
Publicado: (2010)

Pharmacokinetics of plasma-derived C1-esterase inhibitor after subcutaneous versus intravenous administration in subjects with mild or moderate hereditary angioedema: the PASSION study
por: Martinez-Saguer, Inmaculada, et al.
Publicado: (2014)

Subcutaneous C1‐Inhibitor Concentrate for prophylaxis during pregnancy and lactation in a patient with C1‐INH‐HAE
por: Andarawewa, Shimalee, et al.
Publicado: (2021)

Individual approach to long-term therapy in patients with hereditary angioedema (HAE-C1-INH): A case series
por: Andarawewa, S., et al.
Publicado: (2022)

WAO Guideline for the Management of Hereditary Angioedema
por: Craig, Timothy, et al.
Publicado: (2012)

HAE therapies: past present and future
por: Zuraw, Bruce L
Publicado: (2010)

Estimation of EuroQol 5-Dimensions health status utility values in hereditary angioedema
por: Aygören-Pürsün, Emel, et al.
Publicado: (2016)

Socioeconomic burden of hereditary angioedema: results from the hereditary angioedema burden of illness study in Europe
por: Aygören-Pürsün, Emel, et al.
Publicado: (2014)

Hereditary angioedema (HAE) in children and adolescents—a consensus on therapeutic strategies
por: Wahn, V., et al.
Publicado: (2012)

Attenuated androgen discontinuation in patients with hereditary angioedema: a commented case series
por: Maurer, Marcus, et al.
Publicado: (2022)

Management of patients with hereditary angioedema in Germany: comparison with other countries in the Icatibant Outcome Survey
por: Maurer, M., et al.
Publicado: (2018)

453 A 26-Year Review of Long-term Safety of a Human Pasteurized C1 Inhibitor Concentrate
por: Bork, Konrad, et al.
Publicado: (2012)

2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema
por: Bowen, Tom, et al.
Publicado: (2010)

Epidemiology of Bradykinin-mediated angioedema: a systematic investigation of epidemiological studies
por: Aygören-Pürsün, Emel, et al.
Publicado: (2018)

85 Clinical Efficacy of Recombinant Human C1 Inhibitor in Patients with Acute Hereditary Angioedema Attacks
por: Reshef, Avner, et al.
Publicado: (2012)

Long-term prophylaxis with lanadelumab for HAE: authorization for temporary use in France
por: Fain, Olivier, et al.
Publicado: (2022)

Canadian hereditary angioedema guideline
por: Betschel, Stephen, et al.
Publicado: (2014)

Clinical characteristics and burden of illness in patients with hereditary angioedema: findings from a multinational patient survey
por: Mendivil, Joan, et al.
Publicado: (2021)

Treatment of hereditary angioedema with recombinant human C1 Inhibitor in a real-life setting: the experience of the HAE Centre in Milan
por: Zanichelli, Andrea, et al.
Publicado: (2015)

The symptom experience of hereditary angioedema (HAE) patients beyond HAE attacks: literature review and clinician interviews
por: Jean-Baptiste, Milenka, et al.
Publicado: (2022)

Real-world outcomes in hereditary angioedema: first experience from the Icatibant Outcome Survey in the United Kingdom
por: Longhurst, Hilary J., et al.
Publicado: (2018)

Mitigating Disparity in Health-care Resources Between Countries for Management of Hereditary Angioedema
por: Jindal, Ankur Kumar, et al.
Publicado: (2021)

The international WAO/EAACI guideline for the management of hereditary angioedema – The 2021 revision and update
por: Maurer, Marcus, et al.
Publicado: (2022)

C1 inhibitor deficiency: 2014 United Kingdom consensus document
por: Longhurst, H J, et al.
Publicado: (2015)

HAE patient self-sampling for biomarker establishment
por: Förster, Toni M., et al.
Publicado: (2021)

A randomized trial of human C1 inhibitor prophylaxis in children with hereditary angioedema
por: Aygören‐Pürsün, Emel, et al.
Publicado: (2019)

Introduction: New Perspectives in Hereditary Angioedema (HAE): Molecular Mechanisms & Therapeutic Choices: A CME Symposium Presented at the 2009 World Allergy Congress, Buenos Aires, Argentina, December 9, 2009
por: Zuraw, Bruce L, et al.
Publicado: (2010)

Phase II study results of a replacement therapy for hereditary angioedema with subcutaneous C1‐inhibitor concentrate
por: Zuraw, B. L., et al.
Publicado: (2015)

Primary vs. Secondary Antibody Deficiency: Clinical Features and Infection Outcomes of Immunoglobulin Replacement
por: Duraisingham, Sai S., et al.
Publicado: (2014)

Long‐term safety of icatibant treatment of patients with angioedema in real‐world clinical practice
por: Zanichelli, A., et al.
Publicado: (2017)

Laryngeal edema is common in HAE and demands preventive measures
por: Rosario, Cristine Secco, et al.
Publicado: (2015)

International consensus on the diagnosis and management of pediatric patients with hereditary angioedema with C1 inhibitor deficiency
por: Farkas, H., et al.
Publicado: (2016)

83 Hereditary Angioedema and Normal C1-Inhibitor (HAE TYPE III): A Novel Mutation in the Coagulation Factor 12 Gene
por: Bork, Konrad, et al.
Publicado: (2012)

Dedicated call center (SOS-HAE) for hereditary angioedema attacks: study protocol for a randomised controlled trial
por: Javaud, Nicolas, et al.
Publicado: (2016)

Exploring the HME and HAE1 efflux systems in the genus Burkholderia
por: Perrin, Elena, et al.
Publicado: (2010)

Long‐term safety and effectiveness of berotralstat for hereditary angioedema: The open‐label APeX‐S study
por: Farkas, Henriette, et al.
Publicado: (2021)

Cost-effectiveness model for on-demand treatment of hereditary angioedema (HAE) attacks
por: Tyson, Christopher, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_o8e754q8l49regarsb8qhsa03f